| scholarly article | Q13442814 |
| P50 | author | Marcello Tonelli | Q28360280 |
| Andrew Tonkin | Q60629666 | ||
| P2093 | author name string | John Simes | |
| Marc Pfeffer | |||
| Gary Curhan | |||
| Curt Furberg | |||
| Anthony Keech | |||
| Chris Isles | |||
| Frank Sacks | |||
| Malcolm West | |||
| Jim Shepherd | |||
| Chris Packard | |||
| Tim Craven | |||
| P433 | issue | 12 | |
| P304 | page(s) | 3748-3754 | |
| P577 | publication date | 2005-10-26 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Effect of pravastatin in people with diabetes and chronic kidney disease | |
| P478 | volume | 16 |
| Q26747559 | 2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation) |
| Q35860695 | A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. |
| Q37622061 | An update on the lipid nephrotoxicity hypothesis |
| Q44761541 | Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey. |
| Q35017383 | Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus |
| Q91900610 | Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats |
| Q37702722 | Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease |
| Q54982565 | Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. |
| Q37454373 | Cardiovascular risk and management in chronic kidney disease |
| Q36776175 | Chronic kidney disease and its complications |
| Q24642788 | Chronic kidney disease mineral and bone disorder in children |
| Q34402661 | Chronic kidney disease: mineral and bone disorder in children |
| Q53519441 | Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). |
| Q54894051 | Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease. |
| Q58868133 | Documento de consenso para la detección y manejo de la enfermedad renal crónica |
| Q36577189 | Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? |
| Q37789931 | Dyslipidemia in renal disease: Causes, consequences and treatment |
| Q33776176 | Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials |
| Q36667186 | Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q37873794 | Evidence-based statin prescription for cardiovascular protection in renal impairment. |
| Q24194514 | HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis |
| Q36814866 | Hypertension and kidney protection in the elderly: what is the evidence in 2007? |
| Q37704388 | Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy |
| Q52650772 | Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation. |
| Q36772445 | Lipoprotein metabolism in chronic renal insufficiency |
| Q37838899 | Long-term diabetic complications may be ameliorated by targeting Rho kinase |
| Q89741990 | Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology |
| Q50179675 | Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients |
| Q54568444 | Managing chronic kidney disease in type 2 diabetes in family practice. |
| Q43058587 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials |
| Q49908584 | Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease |
| Q34286311 | Population based screening for chronic kidney disease: cost effectiveness study |
| Q28213669 | Protection of renal function in diabetics |
| Q37357219 | Renal dysfunction potentiates foam cell formation by repressing ABCA1. |
| Q58947441 | Reporting of Interaction |
| Q35108893 | Rosuvastatin in diabetic hemodialysis patients |
| Q46794001 | Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis |
| Q46526929 | Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway |
| Q37676827 | Slowing the progression of chronic kidney disease |
| Q90164224 | Statin prescription among patients with type 2 diabetes in Botswana: findings and implications |
| Q38176142 | Statins in chronic kidney disease: cardiovascular risk and kidney function |
| Q37986355 | Statins in the management of dyslipidemia associated with chronic kidney disease |
| Q37883015 | Statins, inflammation and kidney disease |
| Q43746740 | The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects |
| Q42912193 | The lipid story in chronic kidney disease: a long story with a happy end? |
Search more.